THE CONSEQUENCES OF UNDERREPRESENTATION IN CLINICAL TRIALS
Put simply, underrepresentation of anyone – male or female, old or young, and any ethnicities – means that payers will not actually know if the treatment or drug they’re investigating works for everyone in their local health economy. And that’s not okay.
In 2019, of the ~46,000 clinical research volunteers involved in clinical trials that resulted in novel drug approvals only 9% were African American, only 9% were Asian, and just 18% were Hispanic.
The lack of representation of these populations couldn’t be clearer.
Ethnic minorities are underrepresented in clinical research and that needs to change. But first, it’s important to understand why this is happening. And where better to start than with speaking to real people across a wide range of cultures and religions to get their thoughts, feelings and experiences?
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges.
JOIN THE MOVEMENT
We regularly produce reports and thought leadership articles discussing the latest trends and developments in diversity and inclusion. Sign up with your name and email address to receive our updates
We value your privacy. Your personal information will be kept confidential and will never be sold to third parties. It will only be used for communications you request related to Demand Diversity.
